Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Bristol-Myers Squibb
(NY:
BMY
)
45.98
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EDT, Jul 30, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Bristol-Myers Squibb
< Previous
1
2
3
4
5
6
7
8
9
...
77
78
Next >
Stock Market Today: S&P 500, Nasdaq To Open Higher After Robust Meta, Microsoft Earnings—Investors Await Apple, Amazon Results
Today 5:50 EDT
U.S. stock futures rose on Thursday after ending on a mixed note on Wednesday. Futures of major benchmark indices were higher, except for the small-cap gauge Russell 2000.
Via
Benzinga
Topics
Stocks
Earnings Scheduled For July 31, 2025
Today 4:32 EDT
Via
Benzinga
Dow Falls Over 150 Points After Powell's Comments On Rate Cuts: Investor Sentiment Declines, But Fear Index Remains In 'Greed' Zone
Today 3:03 EDT
US stocks fell on Wednesday, with the Dow dropping over 150 points after Fed Chair Powell's comments. Fear Index remained in Greed zone.
Via
Benzinga
Topics
Economy
Stocks
Microsoft, Apple And 3 Stocks To Watch Heading Into Thursday
Today 2:09 EDT
U.S. stock futures up, Apple, Amazon, Meta report strong earnings, Microsoft beats forecast, Bristol-Myers Squibb to release results.
Via
Benzinga
Bristol-Myers Squibb Earnings Preview
July 30, 2025
Via
Benzinga
Retail Chatter On BMY Doubles In 24 Hours With Drug Failing To Meet Primary Goal: Here's What Investors Are Thinking
July 18, 2025
Via
Stocktwits
Bristol Myers Squibb: A Stock with Potential Amid Challenges
July 30, 2025
Via
The Motley Fool
Got $500? 3 Blue Chip Dividend Stocks to Buy and Hold Forever
July 30, 2025
Being a great investor doesn't have to be complicated or expensive.
Via
The Motley Fool
Topics
Intellectual Property
3 Low-Volatility Stocks We Find Risky
July 30, 2025
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.
Via
StockStory
Bristol-Myers Squibb (BMY) Q2 Earnings: What To Expect
July 29, 2025
Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) will be reporting results this Thursday morning. Here’s what you need to know.
Via
StockStory
Topics
Artificial Intelligence
Bristol Myers Squibb and Bain Capital Create New Company Dedicated to Developing Innovative Immunology Therapies that Address the Unmet Medical Needs of Patients
July 28, 2025
From
Bristol Myers Squibb
Via
Business Wire
Why Is ATAI Life Sciences Stock Trading Lower On Monday?
July 28, 2025
Recognify's CIAS trial for inidascamine missed its main endpoint but showed positive signals in cognitive domains and had a favorable safety profile.
Via
Benzinga
Biotech Is Booming, and This Undervalued REIT Stands to Gain
July 25, 2025
Via
The Motley Fool
Explore the top gainers and losers within the S&P500 index in today's session.
July 25, 2025
Let's delve into the developments on the US markets in the middle of the day on Friday. Below, you'll find the top gainers and losers within the S&P500 index during today's session.
Via
Chartmill
Cristian Massacesi, M.D., Joins Bristol Myers Squibb as Executive Vice President, Chief Medical Officer and Head of Development
July 25, 2025
From
Bristol Myers Squibb
Via
Business Wire
Warren Buffett Owns 10 High-Yield Dividend Stocks. Here's the Best of the Bunch.
July 25, 2025
Via
The Motley Fool
2 Cash-Producing Stocks to Keep an Eye On and 1 We Find Risky
July 25, 2025
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
Via
StockStory
Topics
Economy
Branded Pharmaceuticals Stocks Q1 Recap: Benchmarking Supernus Pharmaceuticals (NASDAQ:SUPN)
July 24, 2025
Wrapping up Q1 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Supernus Pharmaceuticals (NASDAQ:SUPN) and its peers.
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
Jim Cramer Praises Lowe's CEO, As For CrowdStrike: 'I'll See You At $1000'
July 24, 2025
On CNBC's "Mad Money Lightning Round," Jim Cramer praised home improvement retailer Lowe's Companies and CrowdStrike Holdings.
Via
Benzinga
Winners And Losers Of Q1: Zoetis (NYSE:ZTS) Vs The Rest Of The Branded Pharmaceuticals Stocks
July 23, 2025
Wrapping up Q1 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Zoetis (NYSE:ZTS) and its peers.
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
Q1 Earnings Recap: Bristol-Myers Squibb (NYSE:BMY) Tops Branded Pharmaceuticals Stocks
July 23, 2025
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Bristol-Myers Squibb (NYSE:BMY) and the best...
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
Peering Into Bristol-Myers Squibb's Recent Short Interest
July 23, 2025
Via
Benzinga
A Look Into Bristol-Myers Squibb Inc's Price Over Earnings
July 22, 2025
Via
Benzinga
Trump Tariffs Forces AstraZeneca To Bring Substantial Pharmaceutical Production To US
July 22, 2025
AstraZeneca plans a $50 billion investment in U.S. facilities by 2030, including a Virginia plant focused on weight loss and metabolic drugs.
Via
Benzinga
Topics
Government
Why Replimune's Surprise Rejection Rattled Wall Street, And Cratered Its Stock
July 22, 2025
The company had lined up a priority review in the hopes of winning an accelerated approval for its melanoma treatment.
Via
Investor's Business Daily
FDA Rejects Replimune's Blood Cancer Drug, Stock Sinks
July 22, 2025
Replimune stock fell after the FDA rejected its RP1 application, citing flaws in the trial design and lack of substantial evidence for approval.
Via
Benzinga
3 Value Stocks We’re Skeptical Of
July 22, 2025
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued...
Via
StockStory
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
July 21, 2025
Via
Benzinga
Bristol Myers Squibb’s Supplemental New Drug Application (sNDA) for Sotyktu (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis Accepted for Review Across Four Regions Globally
July 21, 2025
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers' Drug Flunks Blood Cancer-Associated Anemia Trial
July 18, 2025
Bristol Myers' Reblozyl missed its primary goal in a Phase 3 anemia trial but showed positive secondary outcomes in myelofibrosis patients.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
77
78
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.